BR112012022672A2 - anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira, composição farmacêutica, uso do anticorpo, métodos para inibir o crescimento e/ou a proliferação de uma célula de tumor, para produzir um anticorpo, para detectar a presença de c-met em uma amostra, kit para detectar a presença de c-met em uma amostra, e, anticorpo anti-idiotípico - Google Patents

anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira, composição farmacêutica, uso do anticorpo, métodos para inibir o crescimento e/ou a proliferação de uma célula de tumor, para produzir um anticorpo, para detectar a presença de c-met em uma amostra, kit para detectar a presença de c-met em uma amostra, e, anticorpo anti-idiotípico

Info

Publication number
BR112012022672A2
BR112012022672A2 BR112012022672A BR112012022672A BR112012022672A2 BR 112012022672 A2 BR112012022672 A2 BR 112012022672A2 BR 112012022672 A BR112012022672 A BR 112012022672A BR 112012022672 A BR112012022672 A BR 112012022672A BR 112012022672 A2 BR112012022672 A2 BR 112012022672A2
Authority
BR
Brazil
Prior art keywords
clutch
hydraulic pressure
transmission mechanism
antibody
target output
Prior art date
Application number
BR112012022672A
Other languages
English (en)
Other versions
BR112012022672B1 (pt
Inventor
Frank Labrijn Aran
De Goeij Bart
Van Den Brink Edward
Van De Winkel Jan
Schuurman Janine
J Neijssen Joost
Parren Paul
M A Hoet Rene
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of BR112012022672A2 publication Critical patent/BR112012022672A2/pt
Publication of BR112012022672B1 publication Critical patent/BR112012022672B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira, composição farmacêutica, uso do anticorpo, métodos para inibir o crescimento e/ou a proliferação de uma célula de tumor, para produzir um anticorpo, para detectar a presença de c-met em uma amostra, kit para detectar a presença de c-met em uma amostra, e, anticorpo anti-idiotípico. dispositivo de controle para um mecanismo de transmissão, caracterizado pelo fato de que é para controlar um mecanismo de transmissão escalonada (30), que inclui uma primeira embreagem (32) a ser acoplada na partida, e uma segunda embreagem (33), diferente da primeira embreagem (32), e é travado quando uma pressão hidráulica é suprida à primeira embreagem (32) e à segunda embreagem (33), e a primeira embreagem (32) e a segunda embreagem (33) são completamente acopladas, compreendendo: um meio de controle de pressão hidráulica (12) adaptado para controlar um pressão hidráulica suprida ao mecanismo de transmissão escalonada (30), de modo que a primeira embreagem (32) seja colocada em um estado completamente acoplado, e a segunda embreagem (33) seja colocada em um estado de travamento deslizante, no qual a segunda embreagem (33) não fica completamente acoplada, no caso de um retorno de um controle de parada inativa, no qual um motor (1) é automaticamente parado. dispositivo de controle para um mecanismo de transmissão, de acordo com a revivindicação1, caracterizado pelo fato de que o meio de controle de pressão hidráulica (12) começa a reduzir a pressão hidráulica, suprida à segunda embreagem (33), quando uma proporção aumentada de um avelocidade de rotação de motor por unidade de tempo fica menor do que um primeiro valor predeterminado. dispositivo de controle para um mecanismo de transmissão, de acordo com a reinvidicação 1 ou 2 , caracterizado pelo fato de que o meio de controle de pressão hidráulica (12) controla a pressão hidráulica, suprida à segunda embreagem (33), de modo que uma proporção diminuída da pressão hidráulica, suprida à segunda embreagem (33), por unidade de tempo se torna um segundo valor predeterminado. dispositivo de controle para um mecanismo de transmissão, de acordo com a reivindicação 1 ou 2, caracterizado pelo fato de que o meio de controle de pressão hidráulica (12): inclui o meio de cálculo de torque de saída alvo (12), adaptado para calcular um torque de saída alvo por adição de um terceiro valor predeterminado a um torque de saída alvo calculado da última vez; e controla a pressão hidráulica suprida à segunda embreagem (33), com base no torque de saída alvo calculado pelo meio de cálculo de torque de saída alvo (12). dispositico de controle para um mecanismo de transmissão, de acordo com a reinvidicação 1, caracterizado pelo fato de que o meio de controle hidráulico (12); inclui o meio de cálculo de torque de saída alvo (120, adaptado para calcular um torque de entrada do mecanismo de transmissão escalonada, com base em uma velocidade de rotação de motor, e calcular um torque de saída alvo do mecanismo de transmissão escalonada (30), com base em um desvio entre o torque de entrada do mecanismo de transmissão escalonada (30), calculada nesse momento, e o torque de entrada do mecqanismo de transmissão escalonada (30), calculado da última vez, e um quatro valor predeterminado; e controla a pressão hidráulica suprida à segunda embreagem (33), com base no torque de saída alvo calculado pelo meio de cálculo de torque de saída alvo (12). dispositivo de controle para um mecanismo de transmissão, de acordo com a reivindicação 5, caracterizado pelo fato de que o meio de controle de torque de saída alvo (12) calcula o torque de saída alvo, nesse momento, por adição do desvio para o torque de saída alvo, calculado da última vez, quando o desvio é maior do que o quarto valor predeterminado, ou por adição do quarto valor predeterminado para o torque de saída alvo, calculado da última vez, quando o desvio é menor do que o quarto valor predeterminado. dispositivo de controle para um mecanismo de transmissão, de acordo com qualquer uma das reivindicações de 1 a 6, caracterizado pelo fato de que compreende ainda o meio de detecção de gradiente (47), adaptado para detectar um gradiente de uma superfície de via de rolamento, em uma direção de deslocamento de um veículo, em que: uma pressão hidráulica inicial aumenta na medida em que um gradiente ascendente da superfície da via de rolamento, na direção de deslocamento do veículo, aumenta. dispositivo de controle para um mecanismo de transmissão, de acordo com qualquer uma das reivindicações de 1 a 7, caracterizado pelo fato de que compreende ainda o meio de detecção de gradiente (47), adaptado para detectar um gradiente de uma superfície de via de rolamento, em uma direção de deslocamento de um veículo, em que: o meio de controle de pressão hidráulica (12) faz com que a pressão hidráulica, suprida à sentido de incongruidade (33), seja reduzida de uma pressão hidráulica inicial, a uma sincronização mais cedo, na medida em que um gradiente ascendente da superfície da via de rolamento, na direção de deslocamento do veículo, aumenta. dispositivo de controle para um mecanismo de transmissão, de acordo com qualquer uma das reivindicações de 1 a 8, caracterizado pelo fato de que compreende ainda o meio de detecção de gradiente (47), adaptado para detectar um gradiente de uma superfície de via de rolamento, em uma direção de deslocamento de um veículo, em que: o meio de controle de pressão hidráulica (12) reduz uma proporção diminuída da pressão hidráulica, suprida à segunda embreagem (33), por unidade de tempo, na medisa em que um gradiente ascendente da superfície de via de rolamento, na direção de deslocamento do veículo, aumenta. dispositivo de controle para um mecanismo de transmissão, de acordo com qualquer uma das reivindicações de 1 a 9, caracterizado pelo fato de que o meio de controle de pressão hidráulica (12) inicia o suprimento da pressão hidráulica à segunda embreagem (33), de modo que a segunda embreagem (33) seja ajustada no estado de travamento deslizante, quando um veículo pára. dispositivo de controle para um mecanismo de transmissão, de acordo com qualquer uma das reivindicações de 1 a 10, caracterizado pelo fato de que o controle de parda inativa é iniciado, após a segunda embreagem (33) ser ajustada no estado de travamento deslizante. método de controle para um mecanismo de transmissão escalonada, que inclui uma primeira embreagem (32), a ser acoplada na partida, e uma segunda embreagem (33), diferente da primeira embreagem (31), e que é travado quando uma pressão hidráulica é suprida à primeira embreagem (32) e à segunda embreagem (33), e a primeira embreagem (32) e a segunda embreagem (33) são completamente acopladas, caracterizado pelo fato de que compreende: controle de uma pressão hidráulica suprida ao mecanismo de transmissão, de modo que a primeira embreagem (32) seja colocada em um estado completamente acoplado, e a segunda embreagem (33) seja colocada em um estado de travamento deslizante, no qul a segunda embreagem (33) não fica completamente acoplada, no caso de um retorno de um controle de parada inativa, no qual um motor (1) é automaticamente parado.
BR112012022672A 2010-03-10 2011-03-10 anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira procariótica recombinante, composição farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, para detectar a presença de c-met em uma amostra, e, kit para detectar a presença de c-met em uma amostra BR112012022672B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31262210P 2010-03-10 2010-03-10
DKPA201000191 2010-03-10
DKPA201000862 2010-09-24
PCT/EP2011/053646 WO2011110642A2 (en) 2010-03-10 2011-03-10 Monoclonal antibodies against c-met

Publications (2)

Publication Number Publication Date
BR112012022672A2 true BR112012022672A2 (pt) 2017-02-14
BR112012022672B1 BR112012022672B1 (pt) 2020-04-14

Family

ID=44342987

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022672A BR112012022672B1 (pt) 2010-03-10 2011-03-10 anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira procariótica recombinante, composição farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, para detectar a presença de c-met em uma amostra, e, kit para detectar a presença de c-met em uma amostra

Country Status (14)

Country Link
US (6) US9068011B2 (pt)
EP (3) EP2545077B1 (pt)
JP (4) JP6055312B2 (pt)
KR (2) KR101814571B1 (pt)
CN (2) CN103003307B (pt)
AU (4) AU2011226103C1 (pt)
BR (1) BR112012022672B1 (pt)
CA (2) CA2791863C (pt)
EA (1) EA201201273A1 (pt)
IL (1) IL221408B (pt)
MX (1) MX340295B (pt)
NZ (1) NZ602294A (pt)
SG (2) SG183190A1 (pt)
WO (1) WO2011110642A2 (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340295B (es) 2010-03-10 2016-07-05 Genmab As Anticuerpos monoclonales anti-c-met.
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
IL250396B (en) 2011-06-23 2022-06-01 Ablynx Nv Techniques for predicting, detecting, and reducing A-specific protein interference in assays involving single immunoglobulin variable domains
CN103619878B (zh) 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
JP2014530201A (ja) * 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
US9346884B2 (en) * 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN103889451B (zh) * 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
WO2013070565A1 (en) * 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
AR088920A1 (es) 2011-11-21 2014-07-16 Genentech Inc Purificacion de anticuerpos anti-c-met
WO2013079973A1 (en) * 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9708601B2 (en) * 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
EP2863946A4 (en) * 2012-06-21 2016-04-13 Sorrento Therapeutics Inc ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EA031184B1 (ru) 2012-11-21 2018-11-30 Янссен Байотек, Инк. БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
EP2943506B1 (en) 2013-01-10 2024-03-13 Genmab B.V. Human igg1 fc region variants and uses thereof
JP2014157056A (ja) * 2013-02-15 2014-08-28 Fujirebio Inc ｃ−ＭＥＴ遺伝子増幅細胞の検出方法
BR112015021462A2 (pt) * 2013-03-06 2017-10-10 Adimab Llc anticorpos biespecíficos anti-c-met tandem fc
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR102277813B1 (ko) * 2013-04-02 2021-07-16 삼성전자주식회사 항 c-Met 항체의 항-이디오타입 항체
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
AU2014334627B2 (en) 2013-10-14 2019-07-25 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
EA039356B1 (ru) * 2013-10-18 2022-01-18 Янссен Байотек, Инк. БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
US10617764B2 (en) 2013-11-21 2020-04-14 Genmab A/S Lyophilized anti-tissue factor antibody-drug conjugates
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
KR101615619B1 (ko) * 2014-08-07 2016-04-26 주식회사 파멥신 c-Met 특이적 인간 항체 및 그 제조방법
US10450376B2 (en) 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
WO2017141243A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP4140492A1 (en) 2015-04-21 2023-03-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
JP2018527903A (ja) * 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Ｇｄｆ１１結合タンパク質およびその使用
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
CN108350078A (zh) * 2015-11-03 2018-07-31 默克专利股份公司 用于提高肿瘤选择性和抑制的双特异性抗体及其用途
SG11201805709RA (en) 2016-01-08 2018-07-30 Scholar Rock Inc Anti-pro/latent myostatin antibodies and methods of use thereof
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP4218804A3 (en) 2016-06-13 2023-09-13 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
EP3471750A4 (en) 2016-06-21 2020-02-26 Janssen Biotech, Inc. CYSTEINE-MODIFIED TYPE III FIBRONECTIN BINDING MOLECULES
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
JP6942179B2 (ja) * 2016-09-29 2021-09-29 田辺三菱製薬株式会社 ｃＭＥＴモノクローナル結合剤、その薬物複合体およびその使用
TWI782930B (zh) * 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
EP3932432A1 (en) 2016-12-14 2022-01-05 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
US20180230218A1 (en) * 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
SI3565592T1 (sl) 2017-01-06 2023-05-31 Scholar Rock, Inc. Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
CN114989305A (zh) * 2017-03-31 2022-09-02 北京智仁美博生物科技有限公司 新型双特异性抗体及其用途
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
BR112019025070A2 (pt) * 2017-05-30 2021-03-23 Chong Kun Dang Pharmaceutical Corp. inovador anticorpo anti-c-met e utilização do mesmo
EP3694545A4 (en) * 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
WO2019182888A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Human pd-l2 antibodies and methods of use therefor
AU2019300911B2 (en) * 2018-07-10 2023-06-01 Genemedicine Co., Ltd. Anti-tumor composition
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
KR102433184B1 (ko) * 2018-12-07 2022-08-17 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
JP7455188B2 (ja) * 2019-07-19 2024-03-25 ウーシー・エックスディシー・シンガポール・プライベイト・リミテッド コンジュゲーションのためのポリペプチド複合体及びその応用
WO2021022304A2 (en) 2019-07-30 2021-02-04 Qlsf Biotherapeutics, Inc. MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε
CA3146933A1 (en) 2019-09-16 2021-03-25 Marcus KELLY Radiolabeled met binding proteins for immuno-pet imaging
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN111620944B (zh) * 2020-06-01 2023-03-21 长春师范大学 一种全人源化抗乙肝病毒单克隆抗体、制备方法及其应用
CN111892656B (zh) * 2020-08-10 2021-02-19 北京鼎成肽源生物技术有限公司 抗人c-Met人鼠嵌合单克隆抗体及其应用
WO2022152289A1 (en) * 2021-01-18 2022-07-21 Wuxi Biologics (Shanghai) Co., Ltd. An engineered antibody and antibody-drug conjugates comprisign same
EP4359446A1 (en) * 2021-06-25 2024-05-01 Academia Sinica Combined cancer therapy with an epithelial cell adhesion molecule (epcam) inhibitor and a hepatocyte growth factor receptor (hgfr) inhibitor
CN113621058B (zh) * 2021-08-19 2023-05-23 中国科学院微生物研究所 黄热病毒抗体及其应用
WO2023034569A1 (en) * 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2024030341A1 (en) 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US835A (en) 1838-07-12 X i i i x
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
EP0507868A4 (en) 1989-12-27 1992-11-04 Us Commerce Diagnostic probe for detecting human stomach cancer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2091700C (en) 1990-09-14 2002-11-19 Jeffrey S. Rubin A non-mitogenic competitive hgf antagonist
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994000764A1 (en) 1992-06-26 1994-01-06 THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES The met proto-oncogene and a method for predicting breast cancer progression
DE69315440T2 (de) 1992-09-18 1998-07-09 Us Gov Health & Human Serv Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie
US5361922A (en) 1993-04-02 1994-11-08 Beckman Instruments, Inc. Centrifuge tubes with snap plugs
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
JP4993834B2 (ja) 2000-06-29 2012-08-08 ノース ショア−ロング アイランド ジューイッシュ ヘルス システム 細胞増殖および血管形成の調節物質、その使用方法および特定方法
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1461082A4 (en) 2001-12-03 2006-06-28 Abgenix Inc ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX)
US20050118165A1 (en) 2001-12-27 2005-06-02 Van Andel Institute; And The Usa As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
WO2004072117A2 (en) 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
PT1636593E (pt) 2003-06-06 2009-06-03 Genentech Inc Modulação da interacção entre a cadeia beta de hgf e c-met
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
CN102838675B (zh) 2003-12-10 2014-07-30 梅达雷克斯有限责任公司 Ip-10抗体及其用途
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
EP1749029B1 (en) 2004-05-27 2011-03-09 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
RS51326B (sr) 2004-08-05 2010-12-31 Genentech Inc. Humanizovani anti-cmet antagonisti
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
ZA200707953B (en) 2005-03-25 2009-06-24 Genenthech Inc Methods and compositions for modulating hyperstabilized c-met
CN102989012B (zh) 2005-03-31 2015-05-13 通用医疗公司 监测和调制hgf/hgfr活性
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
SG10201600950TA (en) 2005-11-28 2016-03-30 Genmab As Recombinant monovalent antibodies and methods for production thereof
CN101379192B (zh) 2006-02-06 2013-07-31 梅思尔斯平移研究有限公司 治疗肿瘤的抗Met单克隆抗体及其片段和载体及相应产品
KR20080113218A (ko) * 2006-03-30 2008-12-29 노파르티스 아게 ｃ―Ｍｅｔ의 항체에 대한 사용 방법 및 조성물
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2008110372A1 (en) * 2007-03-13 2008-09-18 University Of Zurich Monoclonal human tumor-specific antibody
AU2008255387B2 (en) * 2007-05-31 2014-06-26 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
US20100267934A1 (en) 2007-05-31 2010-10-21 Genmab A/S Stable igg4 antibodies
US20080300108A1 (en) 2007-05-31 2008-12-04 Eybergen William N Torque transfer device and system
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
KR20100135780A (ko) * 2008-03-06 2010-12-27 제넨테크, 인크. Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2010037835A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
WO2010064090A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
AR074438A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
MX340295B (es) 2010-03-10 2016-07-05 Genmab As Anticuerpos monoclonales anti-c-met.
EA031184B1 (ru) * 2012-11-21 2018-11-30 Янссен Байотек, Инк. БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies

Also Published As

Publication number Publication date
NZ602294A (en) 2015-04-24
AU2019283925B2 (en) 2021-12-02
WO2011110642A3 (en) 2012-07-05
EP3511342B1 (en) 2024-01-17
KR101814571B1 (ko) 2018-01-04
CN103003307A (zh) 2013-03-27
US9068011B2 (en) 2015-06-30
EP3904391A1 (en) 2021-11-03
JP2018174937A (ja) 2018-11-15
AU2019283925A1 (en) 2020-01-16
US20240084036A1 (en) 2024-03-14
JP7034204B2 (ja) 2022-03-11
MX2012009987A (es) 2012-11-30
IL221408A0 (en) 2012-10-31
AU2011226103B2 (en) 2016-01-28
US20170320962A1 (en) 2017-11-09
US20130216548A1 (en) 2013-08-22
EP2545077B1 (en) 2018-10-31
CN107739407A (zh) 2018-02-27
EP2545077A2 (en) 2013-01-16
US20150329642A1 (en) 2015-11-19
CN107739407B (zh) 2021-07-06
JP6697027B2 (ja) 2020-05-20
JP2020198874A (ja) 2020-12-17
KR20180004292A (ko) 2018-01-10
BR112012022672B1 (pt) 2020-04-14
US20200079872A1 (en) 2020-03-12
EA201201273A1 (ru) 2013-02-28
US9657107B2 (en) 2017-05-23
SG10201501767VA (en) 2015-05-28
WO2011110642A2 (en) 2011-09-15
KR102059663B1 (ko) 2019-12-26
JP2017008041A (ja) 2017-01-12
CA2791863A1 (en) 2011-09-15
KR20130012128A (ko) 2013-02-01
JP6348541B2 (ja) 2018-06-27
AU2017265061B2 (en) 2019-09-19
CA2791863C (en) 2022-06-21
JP2013529059A (ja) 2013-07-18
US11512140B2 (en) 2022-11-29
IL221408B (en) 2020-09-30
MX340295B (es) 2016-07-05
AU2011226103A1 (en) 2012-09-27
AU2011226103C1 (en) 2016-04-28
CA3157780A1 (en) 2011-09-15
EP3511342A1 (en) 2019-07-17
AU2016200093A1 (en) 2016-02-04
CN103003307B (zh) 2017-08-11
JP6055312B2 (ja) 2017-01-11
SG183190A1 (en) 2012-09-27
US20170313782A1 (en) 2017-11-02
AU2017265061A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
BR112012022672A2 (pt) anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira, composição farmacêutica, uso do anticorpo, métodos para inibir o crescimento e/ou a proliferação de uma célula de tumor, para produzir um anticorpo, para detectar a presença de c-met em uma amostra, kit para detectar a presença de c-met em uma amostra, e, anticorpo anti-idiotípico
BR112018009409A2 (pt) método de controle de força de frenagem/acionamento e dispositivo de controle de força de frenagem/acionamento
BR112019000872A2 (pt) métodos para quantificar anticorpos individuais de uma mistura
GB201201222D0 (en) Motor vehicle and method of control of a motor vehicle
BR112015023018A2 (pt) sistema e método para controle de velocidade de veículo
MX2020011640A (es) Controlador electronico para una relacion de una transmision continuamente variable (cvt).
BR0211355A (pt) Cálculo de torque de motor
BR112013001748B1 (pt) Sistema e método de supressão da vibração para veículo acionado eletricamente
GB0514459D0 (en) A method and apparatus for braking and stopping a vehicle having an electric drive
BR112014017903A8 (pt) Método para controlar um sistema de controle de deslocamento para um veículo e sistema de controle de deslocamento para um veículo
BR112016011717B1 (pt) Motor a combustão de quatro tempos, veículo, e, método para controlar um motor a combustão
WO2009083776A3 (en) Controller for engine
US20160332634A1 (en) Apparatus and method of estimating road slope using gravitational acceleration sensor
BR112017011249A2 (pt) método e unidade de controle para ajustar um intervalo de tempo
BR112014011857A2 (pt) método e módulo para determinação de pelo menos um valor de referência para um sistema de controle de veículo
BR112014014987A2 (pt) sistema para controle automatizado de um dispositivo de tração penetrando o solo e método para controlar um dispositivo de tração penetrando o solo
BR112014027423A2 (pt) regulador e sistema para girar um rolo de material de maneira controlada
BR112013029641B1 (pt) método para operar um veículo e suporte legível por computador
BR112014005148A2 (pt) dispositivo de controle para transmissão continuamente variável
BR112015007402A2 (pt) regulação de concentração/fração de substâncias em uma corrente de exaustão
GB201110205D0 (en) A method and system for controlling a motor vehicle
BR112015030084A2 (pt) técnicas de mudança de transmissão interativa
BRPI0519514A2 (pt) dispositivo de controle de regulaÇço de vÁlvula dispositivo de motor, e veÍculo incluindo o mesmo
BR102012023415A8 (pt) Método de resfriamento de ar interno em um veículo, sistema de condicionamento de ar de veículo, e, veículo
BR112015008449A2 (pt) aparelho de acionamento veicular

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2011, OBSERVADAS AS CONDICOES LEGAIS.